The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

These reports have been prepared and issued by Hardman & Co Research Limited (trading as Hardman & Co) and Edison Investment Research Limited ("Edison") for publication in the United Kingdom. These reports and the information and opinions set out in the reports are the independent views of Hardman & Co and Edison at the time of publication and do not necessarily represent the views and opinions of Futura Medical plc (the "Company"). The reports have been produced by Hardman & Co and Edison at the request of the Company. The Company makes no representations as to the accuracy and completeness of the information contained in the reports.

The communication of these reports is a financial promotion for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA") and has not been approved by an authorised person within the meaning of FSMA and may only be communicated in reliance upon an exemption from the financial promotion restriction in section 21 of FSMA. These reports and their contents are exempt from section 21 of FSMA on the basis that they are communicated only to the following kinds of persons:

  • investment professionals (within the meaning of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO"));
  • certified high net worth companies and unincorporated associations (within the meaning of article 49 of the FPO);
  • persons certified by an authorised person as sophisticated investors within the meaning of article 50 of the FPO (but for the avoidance of doubt not those who are self-certified within the meaning of article 50A of the FPO); or
  • a person who is otherwise permitted by law to receive such communications.

A person is a sophisticated investor within the meaning of article 50 of the FPO if he (a) has a current certificate signed by an authorised person (within the meaning of FSMA) to the effect that he is sufficiently knowledgeable to understand the risks associated with an investment in the Company; and (b) has signed a statement, within 12 months from the date on which this report was made available, in the form contained in article 50(1)(b) of the FPO.

Persons who do not fall within the descriptions above are not entitled to view these reports. Where these reports are communicated by any person who is authorised under FSMA to any other person it must be communicated only to persons falling within the descriptions above. If you are uncertain whether or not you fall within the descriptions you should consult a professional adviser for advice.

Investors who choose to invest in the Company do so at their own risk. The Company recommends that if investors are in any doubt about any action that they should take, they should consult with a professional financial adviser authorised by the Financial Conduct Authority to conduct investment business and who specialises in advising on investment in shares and other securities.


I have read and accept the Terms and Conditions: